GlassScriptPhysician profile
Dariush John Orandi
NPI 1538399613
$1,122.48
in general payments reported to CMS, 2019-2025
14 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $128 · 2021: $31.14 · 2022: $57.32 · 2023: $343 · 2024: $304 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $398.77 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $213.68 | 2019-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $181.12 | 2023-2024 | Tezspire |
| Genzyme Corporation | $57.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.46 | 2025 | |
| Genentech USA, INC. | $43.90 | 2024-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $40.00 | 2019-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.14 | 2021 | |
| Csl Behring | $25.00 | 2019 | |
| Alk-Abello, INC | $20.83 | 2024 | Pre-Pen, Alternaria Tenuis, Timothy, Standardized |
| Ars Pharmaceuticals Operations, INC. | $19.24 | 2025 | Neffy |
| Jubilant Hollisterstier LLC | $18.54 | 2019 | |
| Optinose US, INC. | $12.84 | 2019 | |
| Kaleo, INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dariush Orandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.